The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Clinical Implications of Basic Research
PreviousPrevious
Volume 350:1047-1048 March 4, 2004 Number 10
NextNext

Psychotomimetic Effects of Drugs — A Common Pathway to Schizophrenia?
David J. Gerber, Ph.D., and Susumu Tonegawa, Ph.D.

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-PubMed Citation
Researchers have long been interested in identifying a final, common pathway for psychosis. The existence of such a pathway is implied by the fact that various drug intoxications, schizophrenia and bipolar disorders, psychotic depression, severe sensory deprivation, and Alzheimer's disease can all cause similar psychotic phenomena. Fueling the interest in finding a common pathway is the possibility that the side effects of antidopaminergic neuroleptic agents — principally movement disorders, such as tardive dyskinesia — might be averted by precise targeting of molecules downstream of the dopamine receptor. Svenningsson and colleagues1 recently described a candidate pathway in a mouse model.

Focusing . . . [Full Text of this Article]


Source Information

From the Picower Center, Massachusetts Institute of Technology, Boston.



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.